Baltic biotech attracts investors
Enlarge image


Baltic biotech attracts investors

17.09.2012 - The very first Life Science Baltics 2012 attracted twice as many visitors than anticipated. Investors are lured by EU funds, low cost and qualified staff.

The very first Life Science Baltics conference almost 800 life science professionals visiting Vilnius. „That’s almost twice than we expected“, Jelena Suchodumceva, Senior Project Manager at Enterprise Lithuania, told EuroBiotechNews at the conference. According to the organisers from the governmental agency, more than 80% of the attendants came from non-Baltic states such as Israel, Canada, the US or EU member states. A trade fair showcasing the offerings of more than 40 companies and over 100 pre-scheduled B2B meetings reflected the huge interest to invest in the Baltic scene.

At the conference, ThermoFisher Scientific stated it will inaugurate a €16m research and production facility next week on the grounds of former Lithuanian Fermantas AB. Furthermore, Biotechpharma UAB received an €11m cash injection from EU structural funds. The money helped the Lithuanian CMO to build a state-of-the-art biopharmaceutical facility, which will become fully operational next year at Santara Valley, a brand-new life sciences-IT incubator in the country’s capital. The cluster is one of 5 high-tech valleys supported by the Lithuanian government with investments of €400m.

Prof. Dr. Vladas Bumelis, Chairman of Biotechpharma and Lithuanian biotech mastermind, said at the conference that investors are attracted by the strong knowledge base, low cost of goods and the governmental commitment to support the life sciences sector. To become a big fish within the life science scene, however, it would be essential for the many but small firms in the Baltic region to swim in formation. According to Enterprise Lithuania, the country’s life sciences industry has been skyrocketing over the last two decades with an annual growth rate of 22%, and over 80% of the production being exported. Last year, exports from the life sciences sector amounted to €276.2m. Its main export markets were Sweden (21.1% of the total); Germany (10.9%); Italy (8.1%); UK (6.%); Denmark (6.7%); Russia (4.7%); Norway (4.6%); Poland (4.3%); France (4%); and Latvia (2.7%).



09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.31 EUR19.23%


  • THERAMETRICS (CH)0.04 CHF-33.33%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.13 EUR48.6%
  • OREXO (S)66.00 SEK36.9%
  • ZEALAND PHARMA (DK)156.00 DKK22.4%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • TIGENIX (B)0.88 EUR-27.9%


  • KARO BIO (S)43.60 SEK5282.7%
  • CHRONTECH PHARMA (S)0.35 SEK337.5%
  • GALAPAGOS (B)38.43 EUR225.7%


  • NEOVACS (F)0.70 EUR-77.8%
  • BIOTEST (D)19.15 EUR-74.6%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 08.10.2015